GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management

BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.

Extending Evidence

Source: Novo Nordisk oral Wegovy launch, January 2026

Oral formulation launch creates second persistence improvement pathway beyond supply normalization. Injection barrier removal should improve adherence for needle-averse segment, potentially pushing year-one persistence above the 47% benchmark established for injectable semaglutide. Manufacturing at North Carolina facilities indicates supply chain maturity.